| Lennon E Bowen Iv, MD | |
|
6300 E Lake Blvd Ste 201, Vancleave, MS 39565 | |
| (228) 230-2663 | |
| (228) 206-1192 |
| Full Name | Lennon E Bowen Iv |
|---|---|
| Gender | Male |
| Speciality | Neurology |
| Experience | 25 Years |
| Location | 6300 E Lake Blvd Ste 201, Vancleave, Mississippi |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1619919156 | NPI | - | NPPES |
| 646000515 | Other | COMMERCIAL | |
| P00280787 | Other | RAILROAD MEDICARE | |
| 02277207 | Medicaid | MS |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2084N0600X | Psychiatry & Neurology - Clinical Neurophysiology | 18586 (Mississippi) | Secondary |
| 2084N0400X | Psychiatry & Neurology - Neurology | 18586 (Mississippi) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Singing River Health System | Pascagoula, MS | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Bienville Orthopaedic Specialists, Llc | 0547155178 | 47 |
| Singing River Gulfport | 5294154829 | 106 |
News Archive
A news release from the American Health Association (AHA) in the form of a Scientific Advisory, published in the journal Circulation on December 16, 2019, reiterates that replacing saturated fat with polyunsaturated fats is an effective way to keep the arteries healthy by lowering the levels of artery-clogging cholesterol (LDL) in blood.
AFFiRiS announced today the results of a phase II study in Alzheimer patients. AFFiRiS' proprietary compound AD04 is the first drug ever to demonstrate clinical and biomarker effects consistent with disease modification in Alzheimer patients.
Stanford University officials on Tuesday plan to announce a new policy under which pharmaceutical and medical device companies no longer will have the ability to select continuing medical education courses that they seek to finance for physicians at the university's School of Medicine, the New York Times reports.
RaySearch Laboratories AB has entered into an exclusive distribution agreement with AlphaXRT (formerly CMS Alphatech) based in Sydney, Australia and Auckland, New Zealand. The agreement means that AlphaXRT will be fully responsible for marketing, sales and service of RaySearch's proprietary treatment planning system RayStation in Australia and New Zealand from April 1, 2014.
By combining studies on one species of malaria-carrying mosquito, researchers found that no other animals rely solely on them for food.
› Verified 5 days ago
| Entity Name | Singing River Health System |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1083893937 PECOS PAC ID: 3870405194 Enrollment ID: O20031104000435 |
News Archive
A news release from the American Health Association (AHA) in the form of a Scientific Advisory, published in the journal Circulation on December 16, 2019, reiterates that replacing saturated fat with polyunsaturated fats is an effective way to keep the arteries healthy by lowering the levels of artery-clogging cholesterol (LDL) in blood.
AFFiRiS announced today the results of a phase II study in Alzheimer patients. AFFiRiS' proprietary compound AD04 is the first drug ever to demonstrate clinical and biomarker effects consistent with disease modification in Alzheimer patients.
Stanford University officials on Tuesday plan to announce a new policy under which pharmaceutical and medical device companies no longer will have the ability to select continuing medical education courses that they seek to finance for physicians at the university's School of Medicine, the New York Times reports.
RaySearch Laboratories AB has entered into an exclusive distribution agreement with AlphaXRT (formerly CMS Alphatech) based in Sydney, Australia and Auckland, New Zealand. The agreement means that AlphaXRT will be fully responsible for marketing, sales and service of RaySearch's proprietary treatment planning system RayStation in Australia and New Zealand from April 1, 2014.
By combining studies on one species of malaria-carrying mosquito, researchers found that no other animals rely solely on them for food.
› Verified 5 days ago
| Entity Name | Bienville Orthopaedic Specialists, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1689605834 PECOS PAC ID: 0547155178 Enrollment ID: O20040220000834 |
News Archive
A news release from the American Health Association (AHA) in the form of a Scientific Advisory, published in the journal Circulation on December 16, 2019, reiterates that replacing saturated fat with polyunsaturated fats is an effective way to keep the arteries healthy by lowering the levels of artery-clogging cholesterol (LDL) in blood.
AFFiRiS announced today the results of a phase II study in Alzheimer patients. AFFiRiS' proprietary compound AD04 is the first drug ever to demonstrate clinical and biomarker effects consistent with disease modification in Alzheimer patients.
Stanford University officials on Tuesday plan to announce a new policy under which pharmaceutical and medical device companies no longer will have the ability to select continuing medical education courses that they seek to finance for physicians at the university's School of Medicine, the New York Times reports.
RaySearch Laboratories AB has entered into an exclusive distribution agreement with AlphaXRT (formerly CMS Alphatech) based in Sydney, Australia and Auckland, New Zealand. The agreement means that AlphaXRT will be fully responsible for marketing, sales and service of RaySearch's proprietary treatment planning system RayStation in Australia and New Zealand from April 1, 2014.
By combining studies on one species of malaria-carrying mosquito, researchers found that no other animals rely solely on them for food.
› Verified 5 days ago
| Entity Name | Singing River Gulfport |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1861010159 PECOS PAC ID: 5294154829 Enrollment ID: O20201001001497 |
News Archive
A news release from the American Health Association (AHA) in the form of a Scientific Advisory, published in the journal Circulation on December 16, 2019, reiterates that replacing saturated fat with polyunsaturated fats is an effective way to keep the arteries healthy by lowering the levels of artery-clogging cholesterol (LDL) in blood.
AFFiRiS announced today the results of a phase II study in Alzheimer patients. AFFiRiS' proprietary compound AD04 is the first drug ever to demonstrate clinical and biomarker effects consistent with disease modification in Alzheimer patients.
Stanford University officials on Tuesday plan to announce a new policy under which pharmaceutical and medical device companies no longer will have the ability to select continuing medical education courses that they seek to finance for physicians at the university's School of Medicine, the New York Times reports.
RaySearch Laboratories AB has entered into an exclusive distribution agreement with AlphaXRT (formerly CMS Alphatech) based in Sydney, Australia and Auckland, New Zealand. The agreement means that AlphaXRT will be fully responsible for marketing, sales and service of RaySearch's proprietary treatment planning system RayStation in Australia and New Zealand from April 1, 2014.
By combining studies on one species of malaria-carrying mosquito, researchers found that no other animals rely solely on them for food.
› Verified 5 days ago
| Entity Name | Oal Care Of Al, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1720540693 PECOS PAC ID: 1254668031 Enrollment ID: O20210422000100 |
News Archive
A news release from the American Health Association (AHA) in the form of a Scientific Advisory, published in the journal Circulation on December 16, 2019, reiterates that replacing saturated fat with polyunsaturated fats is an effective way to keep the arteries healthy by lowering the levels of artery-clogging cholesterol (LDL) in blood.
AFFiRiS announced today the results of a phase II study in Alzheimer patients. AFFiRiS' proprietary compound AD04 is the first drug ever to demonstrate clinical and biomarker effects consistent with disease modification in Alzheimer patients.
Stanford University officials on Tuesday plan to announce a new policy under which pharmaceutical and medical device companies no longer will have the ability to select continuing medical education courses that they seek to finance for physicians at the university's School of Medicine, the New York Times reports.
RaySearch Laboratories AB has entered into an exclusive distribution agreement with AlphaXRT (formerly CMS Alphatech) based in Sydney, Australia and Auckland, New Zealand. The agreement means that AlphaXRT will be fully responsible for marketing, sales and service of RaySearch's proprietary treatment planning system RayStation in Australia and New Zealand from April 1, 2014.
By combining studies on one species of malaria-carrying mosquito, researchers found that no other animals rely solely on them for food.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Lennon E Bowen Iv, MD 6300 E Lake Blvd Ste 301, Vancleave, MS 39565-6771 Ph: (228) 230-2663 | Lennon E Bowen Iv, MD 6300 E Lake Blvd Ste 201, Vancleave, MS 39565 Ph: (228) 230-2663 |
News Archive
A news release from the American Health Association (AHA) in the form of a Scientific Advisory, published in the journal Circulation on December 16, 2019, reiterates that replacing saturated fat with polyunsaturated fats is an effective way to keep the arteries healthy by lowering the levels of artery-clogging cholesterol (LDL) in blood.
AFFiRiS announced today the results of a phase II study in Alzheimer patients. AFFiRiS' proprietary compound AD04 is the first drug ever to demonstrate clinical and biomarker effects consistent with disease modification in Alzheimer patients.
Stanford University officials on Tuesday plan to announce a new policy under which pharmaceutical and medical device companies no longer will have the ability to select continuing medical education courses that they seek to finance for physicians at the university's School of Medicine, the New York Times reports.
RaySearch Laboratories AB has entered into an exclusive distribution agreement with AlphaXRT (formerly CMS Alphatech) based in Sydney, Australia and Auckland, New Zealand. The agreement means that AlphaXRT will be fully responsible for marketing, sales and service of RaySearch's proprietary treatment planning system RayStation in Australia and New Zealand from April 1, 2014.
By combining studies on one species of malaria-carrying mosquito, researchers found that no other animals rely solely on them for food.
› Verified 5 days ago